Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2020
Reporting Period: This filing is a current report regarding a specific event on June 2, 2020, not a periodic financial report (e.g., 10-K or 10-Q).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disclose the availability of a slide presentation for investor conferences and does not contain financial statements or operational metrics.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document discloses the Company's intent to use a slide presentation (Exhibit 99.1) at a conference on June 2, 2020, and at subsequent investor meetings.
Guidance, Outlook, and Risks
Management Commentary: The filing references a slide presentation attached as Exhibit 99.1, which likely contains management commentary, but the text of the presentation is not included in this filing.
Risks and Contingencies: The filing includes a standard Regulation FD disclosure stating that the information, including the attached exhibit, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the slide presentation (Exhibit 99.1) referenced in the filing, as it is not included in the text of this 8-K.
- Confirm the date and details of the conference held on June 2, 2020, to understand the context of the disclosed information.
- Review subsequent periodic reports (10-Q or 10-K) for actual financial metrics, as this filing contains none.